Poland-based preclinical Contract Research Organisation Selvita SA (WSE: SLV) has completed the acquisition of Fidelta, also a contract research organisation, from Belgium-based Galapagos NV (Euronext &NASDAQ: GLPG), it was reported on Monday.
Selvita SA has acquired 100% of the outstanding shares in Fidelta. The deal is valued at EUR31.2m and the customary adjustments for net cash and working capital.
The acquisition should almost double Selvita's revenues. Fidelta will now be completely consolidated under the Selvita Group, but it will continue to operate under the Fidelta name.
Eli Lilly announces Q1 2026 dividend
Amgen announces Q4 2025 dividend
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses
Thermo Fisher Scientific to acquire Clario Holdings, expanding clinical data capabilities
Nanoform and Revio Therapeutics partner to develop long-acting hydrogel therapy for glioma
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
IP Group positions for future royalties following Pfizer's USD7.3bn acquisition of Metsera
AstraZeneca strikes landmark drug pricing deal with US Government